N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 Inhibitors as Potential Agents for Treatment of Erectile Dysfunction
- 18 March 2000
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 43 (7) , 1257-1263
Abstract
Phosphodiesterase type 5 (PDE5) inhibitors with improved PDE isozyme selectivity relative to sildenafil may result in agents for the treatment of male erectile dysfunction (MED) with a lower incidence of PDE-associated adverse effects. This paper describes the discovery of 14, a PDE5 inhibitor with improved potency and selectivity in vitro compared to sildenafil. This compound shows activity in a functional assay of erectile function comparable to that of sildenafil.Keywords
This publication has 3 references indexed in Scilit:
- The role of phosphodiesterase inhibitors in impotenceExpert Opinion on Investigational Drugs, 1997
- Cyclic nucleotide phosphodiesterases: functional implications of multiple isoformsPhysiological Reviews, 1995
- Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aortaBiochemical Pharmacology, 1986